Cleerly Launches Cleerly ISCHEMIA Solution for Heart Disease Analysis
FDA cleared, evidence-based AI and machine learning-based algorithm detects heart disease-associated ischemia
Cleerly is aware of the lawsuit filed by Heartflow. We are confident in our extensive and well-established intellectual property portfolio and the originality of our technology.
Cleerly has published landmark clinical science that has redefined how cardiovascular disease is understood and treated, which has formed the basis of our novel technologies that provide physicians with actionable insights into their patients’ heart health.
Cleerly was founded on a mission to create a world without heart attacks, and we have never been more focused in our mission and committed to the patients and physicians who count on us.
For any questions, please reach out to press@cleerlyhealth.com
FDA cleared, evidence-based AI and machine learning-based algorithm detects heart disease-associated ischemia
Cleerly, Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023 Data from...
Cleerly joins American Heart Association Center for Health Technology & Innovation Innovators’ Network American Heart Association consortium advances...
Award recognizes Cleerly’s AI-based digital care platform for heart disease analysis at HLTH 2023 Denver – October 11, 2023 -- Cleerly, the company...